Cited by 272Cervical Cancer and HPV ResearchGenital Health and DiseaseReproductive tract infections research

The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

Open access

Basu, Partha, Malvi, Sylla G, Joshi, Smita, Bhatla, Neerja, Muwonge, Richard, Lucas, Eric, Verma, Yogesh, Esmy, Pulikkottil O, Poli, Usha Rani Reddy, Shah, Anand, Zomawia, Eric, Pimple, Sharmila, Jayant, Kasturi, Hingmire, Sanjay, Chiwate, Aruna, Divate, Uma, Vashist, Shachi, Mishra, Gauravi, Jadhav, Radhika, Siddiqi, Maqsood, Sankaran, Subha, Prabhu, Priya Ramesh, Kannan, Thiraviam Pillai Rameshwari Ammal, Varghese, Rintu, Shastri, Surendra S, Anantharaman, Devasena, Gheit, Tarik, Tommasino, Massimo, Sauvaget, Catherine, Pillai, M Radhakrishna, Sankaranarayanan, Rengaswamy·2021·The Lancet Oncology

DOI 10.1016/s1470-2045(21)00453-8PMC PMC8560643

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: A randomised trial designed to compare three and two doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent girls in India was converted to a cohort study after suspension of HPV vaccination in trials by the Indian Government. In this Article, the revised aim of the cohort study was to compare vaccine efficacy of single dose to that of three and two doses in protecting against persistent HPV 16 and 18 infection at 10 years post vaccination. METHODS: In the randomised trial, unmarried girls aged 10-18 years were recruited from nine centres across India and randomly assigned to either two doses or three doses of the quadrivalent HPV vaccine (Gardasil [Merck Sharp & Dohme, Whitehouse Station, NJ, USA]; 0·5 mL administered intramuscularly). After suspension of recruitment and vaccination, the study became a longitudinal, prospective cohort study by default, and participants were allocated to four cohorts on the basis of the number vaccine doses received per protocol: the two-dose cohort (received vaccine on days 1 and 180 or later), three-dose cohort (days 1, 60, and 180 or later), two-dose default cohort (days 1 and 60 or later), and the single-dose default cohort. Participants were followed up yearly. Cervical specimens were collected from participants 18 months after marriage or 6 months after first childbirth, whichever was earlier, to assess incident and persistent HPV infections. Married participants were screened for cervical cancer as they reached 25 years of age. Unvaccinated women age-matched to the married vaccinated participants were recruited to serve as controls. Vaccine efficacy against persistent HPV 16 and 18 infections (the primary endpoint) was analysed for single-dose recipients and compared with that in two-dose and three-dose recipients after adjusting for imbalance in the distribution of potential confounders between the unvaccinated and vaccinated cohorts. This trial is registered with ISRCTN, ISRCTN98283094, and ClinicalTrials.gov, NCT00923702. FINDINGS: Vaccinated participants were recruited between Sept 1, 2009, and April 8, 2010 (date of vaccination suspension), and followed up over a median duration of 9·0 years (IQR 8·2-9·6). 4348 participants had three doses, 4980 had two doses (0 and 6 months), and 4949 had a single dose. Vaccine efficacy against persistent HPV 16 and 18 infection among participants evaluable for the endpoint was 95·4% (95% CI 85·0-99·9) in the single-dose default cohort (2135 women assessed), 93·1% (77·3-99·8) in the two-dose cohort (1452 women assessed), and 93·3% (77·5-99·7) in three-dose recipients (1460 women assessed). INTERPRETATION: A single dose of HPV vaccine provides similar protection against persistent infection from HPV 16 and 18, the genotypes responsible for nearly 70% of cervical cancers, to that provided by two or three doses. FUNDING: Bill & Melinda Gates Foundation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00453-8

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figure 1 Study flow chart HC II=Hybrid Capture II. HPV=human papillomavirus.CC BY · PubMed Central

Figure 2 Incidence of HPV 16 and 18 (A), and HPV 31, 33, and 45 (B) HPV=human papillomavirus.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
Bachmann, M. F., & Jennings, G. T. (2010) · Nature reviews. Immunology · doi:10.1038/nri2868 · Cited by 2,120
Presentation of multivariate data for clinical use: The Framingham Study risk score functions
SULLIVAN, L. M., Massaro, J. M., & D’Agostino, R. B. (2004) · Statistics in Medicine · doi:10.1002/sim.1742 · Cited by 1,756
Epidemiologic Analysis with a Programmable Calculator
Rothman, K. J., Boice, H. D., & Austin, H. D. (1982) · American Journal of Epidemiology · Cited by 1,039
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., Martin, D., Simms, K. T., Bénard, É., Boily, M.-C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30068-4 · Cited by 943
HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019
Bruni, L., Saura‐Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., et al. (2020) · Preventive Medicine · doi:10.1016/j.ypmed.2020.106399 · Cited by 767
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
Kreimer, A. R., Struyf, F., Rosario‐Raymundo, M. R. D., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 316
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
Sankaranarayanan, R., Prabhu, P. R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B. M., Esmy, P. O., Joshi, S., Poli, U. R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00414-3 · Cited by 242
Self-citation
Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial
Kreimer, A. R., Sampson, J. N., Porras, C., Schiller, J. T., Kemp, T. J., Herrero, R., Wagner, S. A., Boland, J. F., Schussler, J. E., Lowy, D. R., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa011 · Cited by 220
In Vivo Mechanisms of Vaccine-Induced Protection against HPV Infection
Day, P. M., Kines, R. C., Thompson, C. D., Jagu, S., Roden, R. B. S., Lowy, D. R., & Schiller, J. T. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.08.003 · Cited by 171
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Sankaranarayanan, R., Joshi, S., Muwonge, R., Esmy, P. O., Basu, P., Prabhu, P., Bhatla, N., Nene, B. M., Shaw, J., Poli, U. R. R., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.087 · Cited by 164
Self-citation

Show all 29 references

Sorted by citations

Items 101–200 of 272

Unraveling Immunological Dynamics: HPV Infection in Women—Insights from Pregnancy
Condrat, C. E., Crețoiu, D., Radoi, V. E., Mihele, D., Țovaru, M., Bordea, C. I., Voinea, S. C., & Suciu, N. (2023) · Viruses · doi:10.3390/v15102011 · Cited by 9
Enhancing equity in cervical screening – initiatives to increase screening participation
Costa, T., Bateson, D. J., & Woo, Y. L. (2024) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000979 · Cited by 8
Human papillomavirus genotype-specific prevalence and infection risks: a 10-year population-based study from the United States
Wheeler, C. M., Adcock, R., Hunt, W. C., Robertson, M., Torrez-Martinez, N. E., McDonald, R. M., Merchasin, E., Jenison, S. A., Saslow, D., Joste, N. E., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae327 · Cited by 8
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis
Aviraj, K. S., Wasnik, A., Gupta, L., Ranjan, A., & Suresh, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02856-6 · Cited by 10
ThinPrep cytologic test combined with HPV typing to evaluate the degree of cervical diseases and the relationship between HPV typing and the pathological results of patients with atypical squamous cells of undetermined significance: a diagnostic test
Wang, L., Song, Q., Liu, Y., & Ou, Q. (2022) · Translational Cancer Research · doi:10.21037/tcr-22-2026 · Cited by 8
The one-dose schedule opens the door to rapid scale-up of HPV vaccination
Zou, Z., & Zhang, L. (2023) · BMC Medicine · doi:10.1186/s12916-023-03097-x · Cited by 8
Socioeconomic and Health-Related Characteristics Associated with Initiation and Completion of Human Papillomavirus Vaccination among Males in the United States: An In-Depth Systematic Review and Meta-Analysis
Okoli, G. N., Soos, A. E., Etsell, K., Moon, A. G., Kimmel, H. J., Grewal, A., Neilson, C. J., Richardson, C. R., & Harper, D. M. (2025) · Behavioral Medicine · doi:10.1080/08964289.2024.2447358 · Cited by 7
Challenges and Opportunities for Global Cervical Cancer Elimination: How Can We Build a Model for Other Cancers?
Adebamowo, C., Rossi, P. G., & Castle, P. E. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473702 · Cited by 13
Comparative effectiveness and immunogenicity of single-dose and multi-dose human papillomavirus vaccination: a systematic review
Jeong, M., & Jang, I. (2025) · BMC Public Health · doi:10.1186/s12889-025-23496-4 · Cited by 7
Efficacy, effectiveness and immunogenicity of reduced HPV vaccination schedules: A review of available evidence
Montroy, J. R., Salvadori, M. I., Forbes, N. E., Dubey, V., Almasri, S., Jirovec, A., Yan, C., Gusić, K., Stevens, A., Young, K., et al. (2024) · Canada Communicable Disease Report · doi:10.14745/ccdr.v50i06a01 · Cited by 7
Leveraging single-dose human papillomavirus vaccination dose-efficiency to attain cervical cancer elimination in resource-constrained settings
Man, I., Georges, D., Basu, P. S., & Baussano, I. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae035 · Cited by 7
Self-citation
Strategies to accelerate the elimination of cervical cancer in British Columbia, Canada: a modelling study
Pataky, R. E., Izadi‐Najafabadi, S., Smith, L., Gottschlich, A., Ionescu, D. N., Proctor, L., Ogilvie, G. S., & Peacock, S. J. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.231682 · Cited by 7
Prioritising access to cancer drugs
Puyat, C. V. M., Eala, M. A. B., Dee, E. C., Tantengco, O. A. G., Cruz, A. R. D. P., Faylona, E. A., Germar, M. J. V., & Sacdalan, D. L. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00637-9 · Cited by 7
Barriers to HPV vaccination among adolescent girls in India: A scoping review
Josten, K., Rose Dhar, R., Reshmi, B., Natti Krishna, V., & Vennila, J. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_1834_2025 · Cited by 6
“Feasibility of single-dose regimens: Studies done by Man et al 16 , Basu et al 10 , and Sankaranarayanan et al 25 etc , on modelling and efficacy of vaccine supported a shift to single-dose strategies.”
Decoding Fujian’s cervical HPV landscape: unmasking dominance of non-16/18 HR-HPV and tailoring prevention strategies at a large scale
Zhang, Y., Li, H., You, Q., Chen, Y., Zhao, Z., Chen, J., Su, Y., Zheng, X., Huan, Y., & Song, J. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1357073 · Cited by 6
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia
Daniels, V., Saxena, K., Patterson‐Lomba, O., Gómez-Liévano, A., Thobari, J. A., Durand, N., & Myers, E. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310591 · Cited by 6
CervicalMethDx: A Precision DNA Methylation Test to Identify Risk of High-Grade Intraepithelial Lesions in Cervical Cancer Screening Algorithms
Palmieri, L., Zamunér, F. T., de Lima, D. G., Gosala, K., Winkler, E., Prashar, Y., Purcell‐Wiltz, A., García-Negrón, A., Ramos-Lopez, A., Romaguera, J., et al. (2025) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-25-0029 · Cited by 6
Modeling the Health Impact and Cost-Effectiveness of a Combined Schoolgirl HPV Vaccination and Cervical Cancer Screening Program in Guangdong Province, China
Huang, Y., Zhang, D., Yin, L., Zhao, J., Li, Z., Lu, J., Zhang, X., Wu, C., & Wu, W. (2024) · Children · doi:10.3390/children11010103 · Cited by 6
Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies
Quang, C., Chung, A. W., Kemp, T. J., Ratu, T., Tuivaga, E., Russell, F. M., Licciardi, P. V., & Toh, Z. Q. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29732 · Cited by 6
A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system
Ma, M., Xia, B., Wang, Z., Hao, Y., Zhang, T., & Xu, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1073892 · Cited by 6
The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20–45 years of age
Wen, T., Xu, X., Pan, C., Hu, S., Zhao, H., Zhang, X., Qiao, Y., & Zhao, F. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2412391 · Cited by 5
Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine
Quang, C., Anderson, J., Russell, F. M., Reyburn, R., Ratu, T., Tuivaga, E., Devi, R., Frazer, I. H., Garland, S. M., Wines, B. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57443-z · Cited by 5
The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination
Bao, W., He, X., Huang, Y., Liu, R., & Li, Z. (2024) · Vaccines · doi:10.3390/vaccines12090956 · Cited by 5
Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis
Drolet, M., Laprise, J., Chamberland, É., Sauvageau, C., Wilson, S. E., Lim, G. H., Ogilvie, G. S., Tuite, A. R., & Brisson, M. (2024) · Canadian Medical Association Journal · doi:10.1503/cmaj.240787 · Cited by 7
Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study
Umutesi, G., Weiner, B. J., Oluoch, L. M., Bukusi, E. A., Onono, M. A., Njoroge, B. W., Mecca, L., Ngure, K., Mugo, N., & Barnabas, R. V. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae031 · Cited by 5
The structural and organizational aspects of human papillomavirus vaccine affecting immunization coverage in Europe: a systematic review
Valdecantos, R. L., Sorrentino, M., Mercogliano, M., Giordano, V., Trama, U., Triassi, M., & Palladino, R. (2025) · BMC Public Health · doi:10.1186/s12889-025-22343-w · Cited by 5
A questionnaire study on disparity of cervical cancer prevention programs in Asia‐Oceania
Tse, K. Y., Ushijima, K., Tan, A. L., Inthasorn, P., Pariyar, J., Chang, C., Domingo, E. J., Konar, H., Kumarasamy, S., Tjokroprawiro, B. A., et al. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15566 · Cited by 6
The research foundation for COVID-19 vaccine development
Messan, K. S., Sulima, P. P., Ghosh, D., & Nye, J. (2023) · Frontiers in Research Metrics and Analytics · doi:10.3389/frma.2023.1078971 · Cited by 5
Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine Trial
Befano, B., Campos, N. G., Egemen, D., Herrero, R., SCHIFFMAN, M. H., Porras, C., Lowy, D. R., Rodríguez, A. C., Schiller, J. T., Ocampo, R., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad064 · Cited by 5
Introduction of HPV vaccine in universal immunization programme of India: A step in the right direction for the elimination of cervical cancer
Bashar, M., & Khan, I. A. (2024) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_26_23 · Cited by 5
The path to elimination: FEBRASGO 2023's targeted strategies against cervical cancer in Brazil
da Silva, A. L., Roteli-Martins, C. M., Speck, N. M. D. G., de Carvalho, N. S., Cândido, E. B., & Teixeira, J. C. (2024) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2024edt02 · Cited by 5
Pathways and processes to adopting or switching to a single-dose HPV vaccination schedule in low- and middle-income countries: a qualitative study
Roy, S., Wysong, M. D., Rosser, E. N., Sheth, I., Geddes, C., Limaye, R. J., & Rosen, J. G. (2025) · PLOS Global Public Health · doi:10.1371/journal.pgph.0004245 · Cited by 4
Effect of human papillomavirus (HPV) vaccine on HPV type replacement and sexual behaviors in the post-vaccine era: A cross-sectional study
Zhang, J., Chen, Y., Chen, S., Hua, C., & Cheng, H. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2583577 · Cited by 5
Advances on two serological assays for human papillomavirus provide insights on the reactivity of antibodies against a cross-neutralization epitope of the minor capsid protein L2
Mariz, F. C., Putzker, K., Sehr, P. A., & Müller, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1272018 · Cited by 4
Developing, Validating, and Testing Non-vaccine–Preventable Human Papillomavirus to Control for Differences in Sexual Behavior When Evaluating HPV Vaccination
Dema, E., Shing, J. Z., Checchi, M., Beddows, S. A., Liu, D., Sierra, M. S., Haas, C. B., Soldan, K., Field, N. M., Kreimer, A. R., et al. (2025) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-24-1775 · Cited by 4
Human papillomavirus vaccine: Success and challenges
Gupta, C., Dolma, K. G., Sherpa, M. L., Bag, A., & Byahut, A. (2025) · Journal of Biosciences · doi:10.1007/s12038-025-00493-8 · Cited by 5
The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints
Stuart, R., Theopold, N., Miall, N., Kobayashi, E., Vernam, S., Taskin, T., & Dull, P. M. (2026) · Vaccine · doi:10.1016/j.vaccine.2025.128187 · Cited by 4
Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines
Schiller, J. T., Kines, R. C., Day, P. M., Çuburu, N., Kreimer, A. R., & Lowy, D. R. (2026) · The Lancet Microbe · doi:10.1016/j.lanmic.2026.101401 · Cited by 4
ESGO Prevention Committee opinion: is a single dose of HPV vaccine good enough?
Kamani, M. O., Kyrgiou, M., Joura, E. A., Zapardiel, I., Grigore, M., Arbyn, M., Preti, M., Planchamp, F., & Gültekin, M. (2023) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2023-004295 · Cited by 4
Knowledge, attitudes and practices of cervical cancer screening among female students enrolled in higher education institutions in Cabo Verde
Rocha, N. S. S., Clara, B. M., Luz, L. M. M., & Martins, M. D. R. O. (2024) · ecancermedicalscience · doi:10.3332/ecancer.2024.1689 · Cited by 4
IAPSM’s Position Paper on the Human Papilloma Virus (HPV) Vaccine for Adult Immunization in India
Shetty, R. S., Nadda, A., Tambe, M., Raut, A. V., Goel, K., Rao, C. R., Mehta, A., Bhardwaj, P., Gupta, M., & Kamath, V. G. (2024) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_738_24 · Cited by 4
HPV vaccine uptake by Young adults in Hanoi, Vietnam: A qualitative investigation
Hao, N. T. M., Khanh, H., Liamputtong, P., Quan, N. K., & Taylor-Robinson, A. W. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100619 · Cited by 4
Streamlining the WHO cervical cancer elimination goal
Harper, D. M., & Rozek, L. S. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00487-3 · Cited by 4
NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice
Sadr-Momtaz, S., Aftabi, M., Behboudi, E., Naderi, M., Hashemzadeh-Omran, A., & Moradi, A. (2023) · BMC Research Notes · doi:10.1186/s13104-023-06445-5 · Cited by 4
Effectiveness of the Human Papillomavirus Vaccine in Extended Age Groups: A Real-World Analysis Based on the Korean HPV Cohort Study
Song, H., Lee, S., Choi, S., & Hur, S. Y. (2025) · Cancers · doi:10.3390/cancers17152561 · Cited by 4
HPV vaccination among gay, bisexual, and other men who have sex with men aged 27–45 years in the United States is potentially Cost-saving
Clay, P. A., Markowitz, L. E., Gopalani, S. V., Baxter, A., Gargano, J. W., DeSisto, C. L., Senkomago, V., Ekwueme, D. U., Islam, M. H., & Chesson, H. W. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127798 · Cited by 3
State-level progress in reducing cervical cancer incidence among US young women between the pre- and post-human papillomavirus vaccination eras
Jiang, C., Rosenberg, P. S., Star, J., Bandi, P., Bednarczyk, R. A., Jemal, A., & Sung, H. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag051 · Cited by 3
Oncogenic infections: targets highly amenable to cancer prevention
Alberts, C. J., Georges, D., Franceschi, S., Baussano, I., Park, J. Y., Rumgay, H., Basu, P. S., & Clifford, G. M. (2025) · JNCI Monographs · doi:10.1093/jncimonographs/lgaf040 · Cited by 3
Self-citation
Same-day human papilloma virus vaccination improves vaccine uptake in a dermatology sexually transmitted infection clinic: A quality improvement-based model for improving vaccination rates
Himeles, J. R., McKenzie, C., Manduca, S., Shaw, K. S., Jones, Z., Nagler, A. R., Pomeranz, M. K., Gutiérrez, D., & Zampella, J. G. (2025) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2025.01.091 · Cited by 3
Genotypic analysis of human papillomavirus in cervical exfoliated cells from women in Zigong
Ma, X., Wu, C., Wu, T., Yu, X., & Song, L. (2025) · Virology Journal · doi:10.1186/s12985-025-02652-7 · Cited by 3
HPV Genotype Trends in Iran: Necessity for a Reevaluation of Prevention Strategies
Shahi, M., Shafaei, A., Ghodsi, M., Esfehani, R. J., & Marjaneh, M. M. (2025) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed10040100 · Cited by 3
Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda
Einarson, T. A., Musana, E., Balonde, J., Lorentzen, K. B., Kallestrup, R., Juncker, M., Damoi, J. O., Nakami, S., & Kallestrup, P. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127089 · Cited by 3
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010–2021): a retrospective study
Na, Y. J., Jeong, O., Seong, J., Lee, J., Lee, S., Hur, S. Y., & Ryou, S.-M. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e56 · Cited by 3
Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9–14 years at 5 years after vaccination
Davis, B. M., Blake, I., Panicker, G., Meites, E., Thompson, G. G., Geis, J., Bruden, D. J. T., Fischer, M., Singleton, R. J., Unger, E. R., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.033 · Cited by 3
RING box protein-1 promotes the metastasis of cervical cancer through regulating matrix metalloproteinases via PI3K/AKT signaling pathway
Luo, W., Li, Y.-W., Li, G., & Yang, M. (2025) · Journal of Molecular Histology · doi:10.1007/s10735-025-10396-5 · Cited by 3
Reproducibility Assessment of Enzyme-Linked Immunosorbent Assays to Detect Anti-HPV16 L1-Specific IgG1, IgG3, IgA, and IgM Antibodies
Matsui, K., Hempel, H., Shelton, G., Ocampo, R., Kemp, T. J., Pan, Y., & Pinto, L. A. (2024) · Vaccines · doi:10.3390/vaccines12101108 · Cited by 2
Human papillomavirus vaccine use in clinical practice - What dermatologists should know as health care providers
Kansal, M., Bhide, D. S., Mahajan, R. S., Madnani, N., Prabhu, S. S., Sengupta, S., Mehrotra, K., Mamatha, P., & Chaturvedi, N. (2025) · Indian Journal of Sexually Transmitted Diseases and AIDS · doi:10.4103/ijstd.ijstd_51_25 · Cited by 2
Transient receptor potential canonical 3 is required for HPV-induced malignant transformation of cervical epithelial cells
Tan, Y., Huang, Q., Zeng, J., Wang, Y., Yang, S., Li, Y., Wei, J., Wei, Y., Zhao, J., & Chen, J. (2026) · Communications Biology · doi:10.1038/s42003-025-09480-z · Cited by 2
Ethical Challenges to Improving Access to Human Papillomavirus Vaccines in Low- and Middle-Income Countries
Eke, A. C., & Kerry, V. B. (2022) · NEJM Evidence · doi:10.1056/evide2200069 · Cited by 2
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
Ángeles, M. A., Boria, F., Shushkevich, A. B., Bizzarri, N., Theofanakis, C., Schivardi, G., Kacperczyk-Bartnik, J. P., Strojna, A. N., Bilir, E., Mahner, S., et al. (2022) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2022-004160 · Cited by 2
Human papillomavirus infection associated with cervical cancer and other malignancies
Sakauchi, D., & Cianciarullo, A. M. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.25.1.0430 · Cited by 2
HPV EĞİTİMİNİN SAĞLIK HİZMETLERİ MESLEK YÜKSEKOKULU ÖĞRENCİLERİNİN HPV FARKINDALIĞI ÜZERİNE ETKİSİ: ÖN TEST-SON TEST DESENİ YAKLAŞIMI
YENİYAPI, A., & Aydın, E. (2024) · ANKEM Dergisi · doi:10.54962/ankemderg.1521011 · Cited by 2
The AOFOG recommendations on human papillomavirus vaccination in the Asia‐Pacific region
Tse, K. Y., Tan, A. L., Subedi, K., Pervin, S., Gupta, K., Tjokroprawiro, B. A., Woo, Y. L., Wilailak, S., Ochiai, K., Lumbiganon, P., et al. (2024) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16034 · Cited by 2
NAMS task force report on cervical cancer
Bhatla, N. (2024) · Annals of the National Academy of Medical Sciences (India) · doi:10.25259/anams_tfr_11_2024 · Cited by 2
Self-citation
Cost-effectiveness analysis of switching from a bivalent to a nonavalent HPV vaccination programme in China: a modelling study
Gao, M. Q., Hu, S., Zhao, X., You, T., Hong, Y., Liu, Y., Qiao, Y., Jit, M., Zhao, F., & Wang, C. (2025) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2025.101499 · Cited by 2
Immune response after one dose of HPV vaccine among girls and boys and the impact of a second dose given after 3 or more years
Guzun, N., Ouakki, M., Panicker, G., Ionescu, I. G., Mayrand, M., Unger, E. R., & Sauvageau, C. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127475 · Cited by 2
Using observational data to explore the hypothesis that a single dose of current HPV vaccines can provide durable protection
Velicer, C. M., Luxembourg, A. T., Chen, Y.-T., Kohn, M. A., & Saah, A. J. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.088 · Cited by 2
Ethical considerations for the modification of routine human papillomavirus immunisation schedules
D’Souza, J., & Nderitu, D. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00367-9 · Cited by 2
Health and economic effects of introducing single-dose human papillomavirus vaccination in IndiaPreprint
de Carvalho, T., Man, I., Georges, D., Saraswati, L., Bhandari, P., Kataria, I., Siddiqui, M., Muwonge, R., Lucas, E., Sankaranarayanan, R., et al. (2023) · medRxiv · doi:10.1101/2023.04.14.23288563 · Cited by 2
Self-citation
The Clinical Effectiveness of One-Dose HPV Vaccine: A meta-analysis of 902,368 vaccinated womenPreprint
Setiawan, D., Nurulita, N. A., Khoirunnisa, S. M., & Postma, M. J. (2023) · medRxiv · doi:10.1101/2023.08.17.23294214 · Cited by 2
Detection of human papillomavirus infection in oral mucosal diseases
Fantozzi, P. J., Romeo, U., Tenore, G., Palaia, G., Ciolfi, C., Pierangeli, A., Gioia, C. R. T. D., & Villa, A. (2024) · JADA Foundational Science · doi:10.1016/j.jfscie.2024.100031 · Cited by 3
Human Papillomaviruses: Benign and Malignant Disease
Garland, S. M., Williamson, A., & Brotherton, J. M. L. (2024) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_69-1 · Cited by 1
Human Papillomavirus Vaccination in the Postpartum Period
Brenner, S. E., Modesitt, S. C., Bednarczyk, R. A., & Dilley, S. E. (2024) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005718 · Cited by 1
Comparative study of triage strategies for women with atypical squamous cells of undetermined significance in the post-vaccine era
Yang, H., Hao, Y., Niu, M., Zheng, J., Jia, X., Zhang, S., Wang, L., Zhang, X., Pan, Q., Feng, X., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1416116 · Cited by 1
Community intervention of a single-dose or 2-dose regimen of bivalent human papillomavirus vaccine in schoolgirls in Thailand: vaccine effectiveness 2 years and 4 years after vaccination
Jiamsiri, S., Rhee, C., Ahn, H. S., Seo, H.-W., Klinsupa, W., Park, S., Lee, J., Premsri, N., Namwat, C., Silaporn, P., et al. (2024) · JNCI Monographs · doi:10.1093/jncimonographs/lgae036 · Cited by 1
Trichomonas vaginalis adhesion protein 33 (TvAP33) promotes HPV infection by upregulating the expression of HPV membrane receptor molecules
Sheng, W., Zhou, J., Zhang, H., Tian, W., Zhang, Y., Yang, Z., Tian, X., Wang, S., Zhang, Z., & Mei, X. (2025) · Acta Tropica · doi:10.1016/j.actatropica.2025.107578 · Cited by 1
Zervixkarzinomprävention durch HPV-Impfung und Früherkennung
Hillemanns, P., Denecke, A., Hachenberg, J., STEINKASSERER, L., & Jentschke, M. (2025) · Forum · doi:10.1007/s12312-025-01456-8 · Cited by 1
Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward
Michael, S. (2025) · Oral Oncology · doi:10.1016/j.oraloncology.2025.107693 · Cited by 1
Preferences and willingness-to-pay for human papillomavirus vaccination among men who have sex with men in China: a discrete choice experiment
Zou, Z., Hu, Y., Yang, H., Min, Z., Cao, Y., Tieosapjaroen, W., Soe, N. N., Latt, P. M., Ong, J. J., Zhuang, G., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127806 · Cited by 1
Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada
Wals, P. D., & Quach, C. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2589214 · Cited by 1
Economic evaluation of the one-dose HPV vaccination program in Nigeria
Gao, T., Farag, M., Agha, S., Mobula, L. M., Hou, X., Li, G., & Zeng, W. (2025) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2025.100675 · Cited by 1
Immune Responses to Human Papillomavirus After Infection and Vaccination
Newton, H. S., Zwick, D. B., Kemp, T. J., & Pinto, L. A. (2026) · Current topics in microbiology and immunology · doi:10.1007/978-3-032-17775-9_1 · Cited by 1
Long-term effectiveness of at least one dose of human papillomavirus vaccine in adolescents: A test-negative case–control study
Kamolratanakul, S., Niyom, S. L., Ayudaya, N. I. N., Ruengprasertkit, C., Horthongkham, N., Sripradit, K., Dhitavat, J., Muangnoicharoen, S., Sunthornchart, S., & Pitisuttithum, P. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108489 · Cited by 1
Decision-making considerations for single-dose HPV vaccination, including drivers of schedule adoption or switch: insights from immunisation stakeholders in 19 low-income and middle-income countries
Rosser, E. N., Sheth, I., Wysong, M. D., Roy, S., Geddes, C., Limaye, R. J., & Rosen, J. G. (2026) · BMJ Global Health · doi:10.1136/bmjgh-2024-018779 · Cited by 1
Clinical research progress and challenges of vaccine for human papillomavirus-associated cancers
Xue, L., Li, X., Guo, X., Xing, H., & Liu, C. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2676391 · Cited by 2
Integrating Cervical Cancer Prevention into HIV Services in Sub-Saharan Africa: A Narrative Review Addressing the Dual Burden Among Women
Ceesay, E., Ntsigouaye, J. A., Onwuka, J. U., Shanshan, Y., Sokale, I. O., Gupta, R., Okeke, M., Okiemy, E. K., Bojang, K. S., & Bélec, L. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag509 · Cited by 1
Back from the Future: Rational Accountabilities for Cytopathology in Pap Test Cervical Cancer Screening Arising from Covid19
Chantziantoniou, N. (2022) · Acta Cytologica · doi:10.1159/000521911 · Cited by 1
Immunogenicity and Safety of One-Dose Human Papillomavirus Vaccine Compared With Two or Three Doses in Tanzanian Girls (DoRIS): An Open-Label, Randomised, Non-inferiority Trial
Watson‐Jones, D., Changalucha, J. M., Whitworth, H. S., Pinto, L. A., Mutani, P., Indangasi, J., Kemp, T. J., Hashim, R., Kamala, B., Wiggins, R. C., et al. (2023) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000001135 · Cited by 1
Quince años de vacunación frente al virus del papiloma humano en España. Actualización
Llop, F. A. M. (2023) · Vacunas · doi:10.1016/j.vacun.2023.05.001 · Cited by 2
The deadlock on HPV vaccination in Japan is almost broken!
Tjalma, W. A. A., Konno, R., & van Heerden, J. (2024) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2024.04.011 · Cited by 1
HPV infection and its correlation with p53 and Bcl-2 among pregnant mothers and their infants
Sen, S. (2024) · Virus Genes · doi:10.1007/s11262-024-02070-x · Cited by 2
Surveillance of High-Risk Type-16 and 18 Human Papillomavirus among HIV Positive and Non-Positive Individuals at Federal Teaching Hospital Ebonyi State Nigeria
Onu, E. N., Ilang, D. C., Azi, C. I., Eze, T. O., Akpa, C. O., Ogbonna, O. E., Agada, S. E., & Onwe, M. C. (2024) · Advances in Microbiology · doi:10.4236/aim.2024.1412045 · Cited by 1
How Cancer Care Developed in India in 75 Years of Independence—Tamil Nadu Scenario
Raj, E. H. (2022) · Indian Journal of Surgical Oncology · doi:10.1007/s13193-022-01504-y · Cited by 1
Attitudes of mothers of preadolescent girls on HPV vaccine in Italy: do we need a turning point?
Calagna, G., Granese, R., Giallombardo, V., Capra, G., Perino, A., Schiattarella, A., Trucchi, C., & Caridi, G. (2022) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.22.05153-3 · Cited by 1
Detection of Human Papillomavirus infection in oral mucosal diseases: a single-center studyPreprint
Fantozzi, P. J., Romeo, U., Tenore, G., Palaia, G., Ciolfi, C., Pierangeli, A., Gioia, C. R. T. D., & Villa, A. (2023) · Research Square · doi:10.21203/rs.3.rs-2818192/v1 · Cited by 1
Target Policy Profile (TPoP)Preprint
Dolley, S., Hartman, D., & Norman, T. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/2whm6
Potential impact of switching from a two- to one-dose gender-neutral routine HPV vaccination program in Canada: A mathematical modeling analysisPreprint
Drolet, M., Laprise, J., Chamberland, É., Sauvageau, C., Wilson, S. E., Lim, G. H., Ogilvie, G. S., Tuite, A. R., & Brisson, M. (2024) · medRxiv · doi:10.1101/2024.05.29.24308112 · Cited by 1
Cervical cancer prevention becomes more efficient
Harper, D. M., & Rozek, L. S. (2021) · International Journal of Cancer · doi:10.1002/ijc.33851
Alternative analysis of the data from a HPV vaccine study in India – Authors' reply
Basu, P. S., & Muwonge, R. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00729-4
Self-citation
HPV-Impfung: eine Dosis genauso wirksam wie 2- bzw. 3-Dosis-Schema
Lorenz, J. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1605-8696

Authors: Basu, P., Malvi, S. G., Joshi, S., Bhatla, N., Muwonge, R., Lucas, E., Verma, Y., Esmy, P. O., Poli, U. R. R., Shah, A., Zomawia, E., Pimple, S., Jayant, K., Hingmire, S., Chiwate, A., Divate, U., Vashist, S., Mishra, G., Jadhav, R., Siddiqi, M., Sankaran, S., Prabhu, P. R., Kannan, T. P. R. A., Varghese, R., Shastri, S. S., Anantharaman, D., Gheit, T., Tommasino, M., Sauvaget, C., Pillai, M. R., & Sankaranarayanan, R.
Affiliations: Centre international de recherche sur le cancer (FR)
Nargis Dutt Memorial Cancer Hospital (IN)
Jehangir Hospital (IN)
All India Institute of Medical Sciences (IN)
Sikkim Manipal University (IN)
Public Health Foundation of India (IN)
Gujarat Cancer & Research Institute (IN)
Homi Bhabha National Institute (IN)
Cancer Foundation of India (IN)
Rajiv Gandhi Centre for Biotechnology (IN)
Fred Hutch Cancer Center (US)
The University of Texas MD Anderson Cancer Center (US)
RTI International (US)
Corresponding author: Basu, Partha
ORCID: Basu, Partha
Bhatla, Neerja
Muwonge, Richard
Lucas, Eric
Verma, Yogesh
Poli, Usha Rani Reddy
Shah, Anand
Zomawia, Eric
Pimple, Sharmila
Divate, Uma
Vashist, Shachi
Mishra, Gauravi
Siddiqi, Maqsood
Prabhu, Priya Ramesh
Varghese, Rintu
Shastri, Surendra S
Anantharaman, Devasena
Gheit, Tarik
Tommasino, Massimo
Sauvaget, Catherine
Pillai, M Radhakrishna
Sankaranarayanan, Rengaswamy
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2021-11
Volume: 22
Issue: 11
Pages: 1518-1529
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(21)00453-8
PMC: PMC8560643
OpenAlex: W3204615344
Cited by: 272
References: 29
Citations by year: 2026: 41 · 2025: 63 · 2024: 72 · 2023: 46 · 2022: 41 · 2021: 9
FWCI: 30.26
Type: journal article
Language: en
Update notices: erratum (2022-01-01)
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: The Lancet Oncology (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, other-oa)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: GlaxoSmithKline
World Health Organization
Centre International de Recherche sur le Cancer
Seventh Framework Programme (FP7-HEALTH-2011-282562)
Bill and Melinda Gates Foundation
Topics: Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Health Sciences › Medicine › Surgery › Genital Health and Disease
Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords: human papillomavirus, HPV16, HPV 18, quadrivalent HPV vaccine, Gardasil, vaccine efficacy, persistent HPV infection, single-dose vaccination, two-dose vaccination, adolescent girls, cervical cancer prevention, cervical cancer screening, India, cervical cancer incidence
MeSH terms: Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Adolescent, Uterine Cervical Neoplasms, Cervix Uteri, Child, Female, Humans, India, Longitudinal Studies, Prospective Studies, Vaccination, Papillomavirus Infections, Human papillomavirus 18, Human papillomavirus 16

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks